Nexentis Technologies Inc.

Nexentis Technologies Inc. develops and operates an AI and data-driven computational biotech platform. It focuses on mitochondrial biology, precision oncology, and inflammatory metabolic diseases. The company biotechnology segment, driven by its proprietary MITOLINE discovery engine and structure-guided virtual screening workflows, is engaged in the discovery and development of small-molecule therapeutics targeting the mitochondrial SLC25 carrier family for resistant cancers and inflammatory metabolic disease indications. The company’s pipeline includes preclinical programs for oncology and metabolic-inflammation, with evidence supporting anti-tumor and anti-inflammatory activity in human-relevant systems. The renewable energy investments segment manages non-core, value-optimizing assets, including investments in solar energy projects across multiple european union countries, utilizing a ready to build business model. In addition, the company provides post-harvest treatment technologies for reducing pathogen contamination in fruits and vegetables. It serves customers in the biotechnology, pharmaceutical, and renewable energy sectors, as well as the agricultural industry. The company operates internationally, with a particular focus on the European Union and Israel. The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.